IMUC
ImmunoCellular Therapeutics, Ltd. [IMUC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMUC Stock Summary
In the News
IMUC Financial details
Company Rating
-
Market Cap
16.1M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-0.09
Forward P/E
-
PEG
-
P/S
-
P/B
0.36
P/C
-
P/FCF
-2.72
Quick Ratio
2.81
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-6.25%
SMA50
-11.76%
SMA100
36.36%
Inst Own
-
Inst Trans
-
ROA
-264%
ROE
-344%
ROC
-4.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.11-0.4
52W High
-
52W Low
-
RSI
52.41
Rel Volume
0.09
Avg Volume
3.35K
Volume
300
Perf Week
12.14%
Perf Month
-7.1%
Perf Quarter
-7.1%
Perf Half Y
52.43%
-
-
-
-
Beta
1.192
-
-
Volatility
0.02%, 0.01%
Prev Close
0%
Price
0.157
Change
0%
Company Profile
- Volume Average 3.35K
- Market Capitalization 16.1M
- Employee 3
- CEO Dr. Irach B. Taraporewala B.S., M.S., Ph.D.
- Headquarters Montvale,NJ,US
- IPO Date 2021-01-08
-
Website
https://www.eompharma.com 
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
